

## ANSWERING REVIEWERS



April 8, 2014

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 8178-edited.doc).

**Title:** Toremifene in the treatment of breast cancer

**Author:** Mika Mustonen, Seppo Pyrhönen, Pirkko-Liisa Kellokumpu-Lehtinen

**Name of Journal:** *World Journal of Clinical Oncology*

**ESPS Manuscript NO:** 8178-edited

The manuscript has been improved according to the suggestions of reviewers:

*1 Revision has been made according to the suggestions of the reviewer*

**(398512):**

-correct "Letrazole" to "Letrozole"

We have corrected terminology.

-consider avoiding "trend in favor of Toremifene" when there is no statistical difference with Tam

We have looked differences carefully, and consider those reaching very close to significance being a positive trend towards a favorable difference.

-add a paragraph (introduction - Toremifene) commenting on the different doses of Toremifene used in studies and the current dose in the adjuvant setting.

We added and clarified data on toremifene high-dose studies.

-a comment on Toremifene and bone health is missing

We have added a paragraph on bone health.

-Discussion: add a comment on the lack of data about using Toremifene in modern hormonal treatment strategies in combination with AIs (switch, extended)

We have added these comments to Discussion.

**(742507):**

This review represents an excellent state-of-the-art summary of current knowledge of the effects of toremifene in treatment of breast cancer. The topic is important, the evaluation of current literature is well prepared. There is only one thing missing - the data suggest that toremifene is basically as effective as tamoxifen. Therefore, what exactly is the conclusion of this review? Are these drugs identical in effects, so it does not matter which one will be used? Or are there less side-effects with one of these? Should they be used in different groups of patients?

We have edited conclusion, and added comments on possible benefits of toremifene use.

*2 References and typesetting were checked and corrected*

Thank you again for publishing our manuscript in the *World Journal of Clinical Oncology*.

Sincerely yours,

A handwritten signature in blue ink, appearing to read 'Mika Mustonen', with a long horizontal flourish extending to the right.

Mika Mustonen, PhD  
Head of Oncology Development, R&D  
Orion Pharma, Orion Corporation  
FIN-02101, Espoo  
Finland  
tel: +358509664804  
E-mail: [mika.mustonen@orionpharma.com](mailto:mika.mustonen@orionpharma.com)